Skip to main content
Contact Us
Subscribe
E-Edition
42°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cue Biopharma Inc
(NQ:
CUE
)
1.840
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cue Biopharma Inc
< Previous
1
2
Next >
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
March 13, 2024
Via
Investor Brand Network
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
February 29, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
November 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
November 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
November 03, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
November 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
September 26, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
August 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
June 14, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Investor Call
June 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
June 05, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
May 08, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
April 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
April 12, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 21, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
March 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
March 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
February 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
February 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
January 23, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
November 22, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.